JP2005508840A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508840A5
JP2005508840A5 JP2002576895A JP2002576895A JP2005508840A5 JP 2005508840 A5 JP2005508840 A5 JP 2005508840A5 JP 2002576895 A JP2002576895 A JP 2002576895A JP 2002576895 A JP2002576895 A JP 2002576895A JP 2005508840 A5 JP2005508840 A5 JP 2005508840A5
Authority
JP
Japan
Prior art keywords
compound
acetylcysteine
pharmaceutically acceptable
combination
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002576895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508840A (ja
Filing date
Publication date
Priority claimed from US09/833,228 external-priority patent/US6566401B2/en
Application filed filed Critical
Publication of JP2005508840A publication Critical patent/JP2005508840A/ja
Publication of JP2005508840A5 publication Critical patent/JP2005508840A5/ja
Pending legal-status Critical Current

Links

JP2002576895A 2001-03-30 2002-03-28 N−アセチルシステイン組成物及び薬剤毒性治療または防止方法 Pending JP2005508840A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28060001P 2001-03-30 2001-03-30
US09/833,228 US6566401B2 (en) 2001-03-30 2001-04-11 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
PCT/US2002/009442 WO2002078627A2 (en) 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011168224A Division JP2011225610A (ja) 2001-03-30 2011-08-01 N−アセチルシステイン組成物及び薬剤毒性治療または防止方法

Publications (2)

Publication Number Publication Date
JP2005508840A JP2005508840A (ja) 2005-04-07
JP2005508840A5 true JP2005508840A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=26960383

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002576895A Pending JP2005508840A (ja) 2001-03-30 2002-03-28 N−アセチルシステイン組成物及び薬剤毒性治療または防止方法
JP2011168224A Pending JP2011225610A (ja) 2001-03-30 2011-08-01 N−アセチルシステイン組成物及び薬剤毒性治療または防止方法
JP2014205506A Pending JP2015078185A (ja) 2001-03-30 2014-10-06 N−アセチルシステイン組成物及び薬剤毒性治療または防止方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011168224A Pending JP2011225610A (ja) 2001-03-30 2011-08-01 N−アセチルシステイン組成物及び薬剤毒性治療または防止方法
JP2014205506A Pending JP2015078185A (ja) 2001-03-30 2014-10-06 N−アセチルシステイン組成物及び薬剤毒性治療または防止方法

Country Status (13)

Country Link
US (2) US6566401B2 (cg-RX-API-DMAC7.html)
EP (1) EP1379232B1 (cg-RX-API-DMAC7.html)
JP (3) JP2005508840A (cg-RX-API-DMAC7.html)
CN (1) CN100464743C (cg-RX-API-DMAC7.html)
AU (1) AU2002255942B2 (cg-RX-API-DMAC7.html)
BR (1) BR0208563A (cg-RX-API-DMAC7.html)
CA (1) CA2442168C (cg-RX-API-DMAC7.html)
ES (1) ES2550094T3 (cg-RX-API-DMAC7.html)
IL (2) IL158181A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03008904A (cg-RX-API-DMAC7.html)
NZ (1) NZ528478A (cg-RX-API-DMAC7.html)
RU (1) RU2291689C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002078627A2 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662863B2 (en) * 2003-06-09 2010-02-16 Alan Andrews Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
US8993627B2 (en) * 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
RU2302236C2 (ru) * 2005-09-09 2007-07-10 Государственное учреждение научно-исследовательский институт Гриппа Российской академии медицинских наук (ГУ НИИ Гриппа РАМН) Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
CN103251631A (zh) * 2008-05-13 2013-08-21 根梅迪卡治疗公司 用于治疗代谢性病症的水杨酸盐(酯)缀合物
BRPI1011593A2 (pt) * 2009-03-16 2016-03-22 Genmedica Therapeutics Sl "combinação farmacêutica, composição farmaceuticamente aceitavél, e, método para tratar um distúrbio metabólico, para tratar doença pulmonar obstrutiva crônica, e para tratar ou prevenir um ou mais distúrbios metabólicos."
AU2010224866C1 (en) * 2009-03-16 2015-01-15 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
SG176053A1 (en) * 2009-05-15 2011-12-29 Intermune Inc Methods of treating hiv patients with anti-fibrotics
WO2011006097A2 (en) * 2009-07-10 2011-01-13 The Brigham And Women's Hospital, Inc. Methods For Treating Toxicity
CN102573463A (zh) * 2009-07-15 2012-07-11 小利兰·斯坦福大学托管委员会 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
WO2013006658A1 (en) * 2011-07-05 2013-01-10 The Brigham And Women's Hospital, Inc. Treatment of acetaminophen-induced liver damage by the administration of modulators of nitric oxide
US8747894B2 (en) 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
EP2854798A4 (en) 2012-05-24 2016-05-11 Mograbi Josef COMPOSITIONS WITH ISOSILYBIN B FOR THE TREATMENT AND PREVENTION OF ACTIVE-INDUCED TOXICITY
EA032777B1 (ru) 2013-12-24 2019-07-31 Вирджиния Коммонвелт Юниверсити Способ предотвращения или лечения почечной недостаточности
WO2016123223A1 (en) * 2015-01-27 2016-08-04 Florengale, Llc Healing topical composition
EP3302580B1 (en) * 2015-05-27 2021-01-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Compositions and methods for reducing the risk of post-imaging pancreatitis
MX389285B (es) 2015-05-28 2025-03-20 Baylor College Medicine Beneficios de la suplementación con n-acetilcisteína y glicina para mejorar los niveles de glutatión.
CA3010915C (en) * 2016-01-11 2024-06-04 Pledpharma Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
SI3411047T1 (sl) * 2016-02-04 2021-09-30 Czap Research And Development, Llc Sredstva za nadzorovano sproščeni in stratificirani kompleks vključitve ciklodekstrina
JP2020502096A (ja) 2016-12-15 2020-01-23 ザンボン ソシエタ ペル アチオニ 抗バクテリア剤(antibacterial agent)として使用するためのn−アセチルシステイン
KR101942568B1 (ko) * 2017-01-24 2019-01-30 주식회사 우성제약 아세트아미노펜을 함유하는 주사제 조성물
JPWO2020129509A1 (ja) * 2018-12-21 2021-11-04 富士フイルム株式会社 光毒性または光アレルギーの測定方法および上記測定方法において使用するための試薬
US11590090B2 (en) 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
GB2588172B (en) * 2019-10-11 2023-05-24 Blackhawk Partners Ltd A pharmaceutical composition comprising cannabinoid
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2023010088A1 (en) 2021-07-28 2023-02-02 Pono Lifestyle Colorado, Llc Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, sars-cov-2 spike proteins, and mrna vaccine spike proteins
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US547457A (en) * 1895-10-08 Trolley-track
IT1141406B (it) * 1980-04-01 1986-10-01 Dob Far Spa Sali della cefapirina con aminoacidi
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
DE3616923A1 (de) 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
IT1248995B (it) * 1990-06-26 1995-02-11 Italfarmaco Spa Composizioni farmaceutiche a base di sali ferrosi
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5762922A (en) * 1994-01-31 1998-06-09 Ludwig Institute For Cancer Research Antioxidants and intracellular gluthathione raising agents for therapeutic treatments
US5475757A (en) * 1994-06-07 1995-12-12 At&T Corp. Secure data transmission method
WO1996019489A1 (en) * 1994-12-19 1996-06-27 Russinsky Limited Compounds
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
FR2744917B1 (fr) 1996-02-16 1998-04-10 Kouchner Gerard Composition therapeutique a base d'acetaminophene
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US5962421A (en) * 1996-05-16 1999-10-05 Zambon, S.A. Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases
JP2002511878A (ja) * 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
DE69932261D1 (de) * 1999-01-04 2006-08-17 Innovata Plc Ruddington P450 / acetaminophen gdept zur krebsbehandlung
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols

Similar Documents

Publication Publication Date Title
JP2005508840A5 (cg-RX-API-DMAC7.html)
RU2003131876A (ru) Композиции n-ацетилцистеина и способы лечения и профилактики токсичности лекарственных средств
JP2572768B2 (ja) レボドパメチルエステルを有効成分とするパ−キンソン病治療剤
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
KR950703951A (ko) 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac)
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2008521784A5 (cg-RX-API-DMAC7.html)
IL300151A (en) Combinations for the treatment of cancer
RU2008137604A (ru) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа
JP2006516571A5 (cg-RX-API-DMAC7.html)
JP2002528502A5 (cg-RX-API-DMAC7.html)
Murty Antiepileptic overdose
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP5403935B2 (ja) 経口用の慢性疼痛予防または治療剤
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
US6281222B1 (en) Compositions and method for treatment of acetaminophen intoxication
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
JP2006104186A (ja) 感冒用医薬組成物
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
Cailleteau Ketoprofen in dentistry: a pharmacologic review
JPWO2020146666A5 (cg-RX-API-DMAC7.html)
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2